Federal Cannabis Reform: Policy, Legislation, and Rescheduling Efforts

Executive Summary

Federal cannabis reform in the United States represents the most consequential shift in drug policy since the Controlled Substances Act of 1970, with legislative momentum building across multiple congressional sessions despite persistent federal-state conflicts. As of May 2026, cannabis remains a Schedule I controlled substance under 21 U.S.C. § 812, creating a legal paradox where 38 states have authorized medical programs and 24 states permit adult-use sales, yet federal law classifies the plant alongside heroin. The disconnect generates an estimated $1.8 billion annually in excess tax burden through Internal Revenue Code Section 280E, blocks interstate commerce, and forces a $30 billion state-legal industry to operate largely in cash. Current reform efforts span rescheduling through the Drug Enforcement Administration, comprehensive legalization bills in Congress, banking access legislation, and incremental measures addressing research barriers and veterans' access. The outcome will determine whether the United States embraces a regulated national market or continues fractured state-by-state expansion under federal prohibition's shadow.

Why Federal Cannabis Reform Matters

Federal cannabis policy affects 128 million Americans living in legalized states, a $30 billion industry employing over 428,000 workers, and millions of patients relying on medical access—yet federal prohibition creates banking deserts, tax inequities, and criminal justice disparities. The stakeholder universe spans extraordinary breadth. State-licensed operators face effective tax rates exceeding 70% because Section 280E of the tax code prohibits business expense deductions for trafficking in Schedule I or II substances, forcing companies to pay federal income tax on gross receipts rather than net income. Multi-state operators like Curaleaf, Trulieve, and Green Thumb Industries cannot access traditional banking services, forcing reliance on cash operations that increase robbery risk and complicate payroll. A 2024 American Bankers Association survey found only 749 of 4,800 federally insured institutions willing to service cannabis clients, despite state legality. Medical patients number approximately 6.7 million across state programs, many treating conditions from epilepsy to PTSD to chemotherapy side effects. Federal prohibition prevents Veterans Affairs physicians from recommending cannabis despite 40% of veterans reporting interest, according to a 2023 VA survey. Research remains constrained by Drug Enforcement Administration cultivation monopolies and National Institute on Drug Abuse review requirements that delay studies by 18-24 months. Criminal justice implications persist even as states legalize. Federal law enforcement made 6,659 cannabis-related arrests in 2024, predominantly for cultivation and distribution crossing state lines. Immigrants face deportation for state-legal cannabis work under the Immigration and Nationality Act's controlled substance provisions. Past convictions—numbering over 8 million since 1990—create barriers to employment, housing, and education absent federal expungement mechanisms. The economic scale demands attention. Legal cannabis generated $3.7 billion in state tax revenue in 2025, funding education, infrastructure, and social equity programs. Federal legalization could unlock $13.6 billion in annual federal tax revenue by 2030, according to Congressional Budget Office projections, while eliminating the estimated $8 billion spent annually on enforcement.

Background and History: From Prohibition to Reform Momentum

Federal cannabis prohibition began with the Marihuana Tax Act of 1937 and calcified under the Controlled Substances Act of 1970, but the modern reform era emerged from California's 1996 medical legalization and accelerated through state-level adult-use laws beginning in 2012.

The Prohibition Era: 1937-1996

The Marihuana Tax Act of 1937 effectively criminalized cannabis through prohibitive taxation and registration requirements, driven by Federal Bureau of Narcotics Commissioner Harry Anslinger's campaign linking cannabis to violence and moral decay. The Act imposed occupational taxes on cultivators, distributors, and physicians, with penalties reaching $2,000 fines and five years imprisonment. The Controlled Substances Act, signed by President Richard Nixon on October 27, 1970, established the modern framework. Cannabis entered Schedule I—substances with high abuse potential, no accepted medical use, and lack of accepted safety for medical supervision. The classification placed cannabis alongside heroin and LSD, above cocaine (Schedule II) and ketamine (Schedule III). Nixon's National Commission on Marihuana and Drug Abuse, chaired by former Pennsylvania Governor Raymond Shafer, recommended decriminalization in 1972, but Nixon rejected the findings. Federal enforcement intensified through the 1980s and 1990s. The Anti-Drug Abuse Act of 1986 established mandatory minimum sentences: five years for 100 plants or 100 kilograms, ten years for 1,000 plants or 1,000 kilograms. The Omnibus Crime Control Act of 1984 expanded civil asset forfeiture, allowing agencies to seize property connected to drug offenses.

The Medical Cannabis Movement: 1996-2012

California's Proposition 215, approved by 56% of voters on November 5, 1996, created the first state medical cannabis program, allowing patients with physician recommendations to possess and cultivate cannabis for eight specified conditions. The Compassionate Use Act directly challenged federal supremacy, setting the stage for decades of federalism conflict. The Supreme Court affirmed federal authority in United States v. Oakland Cannabis Buyers' Cooperative (2001), ruling that medical necessity provided no defense to Controlled Substances Act violations, and Gonzales v. Raich (2005), holding that Congress could regulate purely intrastate cannabis cultivation under the Commerce Clause. Despite these rulings, state programs proliferated: Alaska, Oregon, and Washington authorized medical use in 1998; Maine in 1999; Colorado, Hawaii, and Nevada in 2000. The Obama administration issued the Ogden Memorandum on October 19, 2009, directing federal prosecutors not to focus resources on "individuals whose actions are in clear and unambiguous compliance with existing state laws providing for the medical use of marijuana." Deputy Attorney General David Ogden wrote that prosecution of seriously ill individuals and caregivers was not an efficient use of limited resources. The policy shift, though not binding law, enabled medical programs to expand with reduced federal interference.

The Adult-Use Era: 2012-Present

Colorado and Washington voters approved adult-use legalization on November 6, 2012—Amendment 64 in Colorado passed with 55% support, Initiative 502 in Washington with 56%. Both measures authorized possession of one ounce for adults 21 and older and created regulated commercial markets. The votes represented the first time any jurisdiction worldwide had approved commercial cannabis legalization through democratic referendum. The Obama administration responded with the Cole Memorandum, issued by Deputy Attorney General James Cole on August 29, 2013. The memo outlined eight enforcement priorities—preventing distribution to minors, preventing revenue to criminal enterprises, preventing diversion to non-legal states, preventing state-authorized activity from being a cover for trafficking, preventing violence and firearms in cultivation and distribution, preventing drugged driving, preventing cultivation on public lands, and preventing possession on federal property. States with "strong and effective regulatory and enforcement systems" would not be targeted. Alaska, Oregon, and the District of Columbia legalized in 2014. California, Maine, Massachusetts, and Nevada followed in 2016. Vermont became the first state to legalize through legislature rather than ballot measure on January 22, 2018, when Governor Phil Scott allowed H.511 to become law without signature. The Trump administration rescinded the Cole Memorandum on January 4, 2018, when Attorney General Jeff Sessions issued a one-page memo returning discretion to local U.S. Attorneys. Sessions called the Cole Memo "unnecessary" and said prosecutors should "weigh all relevant considerations" in charging decisions. Despite the policy shift, federal prosecutions of state-compliant operators remained rare, with U.S. Attorneys in legal states declining to pursue cases.

Congressional Action: 2019-2026

The House of Representatives passed the Marijuana Opportunity Reinvestment and Expungement (MORE) Act on December 4, 2020, by a vote of 228-164, marking the first time either chamber approved cannabis legalization. The bill would have removed cannabis from the Controlled Substances Act, imposed a 5% federal sales tax escalating to 8%, and established grant programs for communities impacted by the War on Drugs. The Senate did not consider the measure. The House passed the MORE Act again on April 1, 2022, by 220-204, with three Republicans joining Democrats. Senate Majority Leader Chuck Schumer introduced the Cannabis Administration and Opportunity Act on July 21, 2021, a comprehensive legalization framework, but the bill never received a floor vote. The Secure and Fair Enforcement (SAFE) Banking Act passed the House seven times between 2019 and 2023, most recently as an amendment to the National Defense Authorization Act. The measure would prevent federal banking regulators from penalizing institutions serving state-legal cannabis businesses. Senate opposition, particularly from Republicans concerned about legalization without addressing public health and impaired driving, blocked passage. President Joe Biden initiated administrative rescheduling on October 6, 2022, directing Health and Human Services Secretary Xavier Becerra and Attorney General Merrick Garland to review cannabis scheduling. HHS completed its review in August 2023, recommending rescheduling to Schedule III based on accepted medical use and lower abuse potential than Schedule I or II substances. The DEA published a Notice of Proposed Rulemaking on May 16, 2024, opening a 60-day comment period. As of May 2026, the rescheduling remains under administrative review, with a final rule expected by late 2026.

Key Players in Federal Cannabis Reform

Drug Enforcement Administration

The DEA holds statutory authority under 21 U.S.C. § 811 to schedule controlled substances, making it the gatekeeper for rescheduling cannabis from Schedule I to Schedule III or removing it from the Controlled Substances Act entirely. Administrator Anne Milgram, appointed in 2021, oversees the rescheduling process following HHS's recommendation. The agency's historical opposition to cannabis reform—rooted in decades of enforcement infrastructure and budget allocations—creates institutional resistance, though the agency is bound by the Administrative Procedure Act's notice-and-comment requirements. The DEA's 2024 Notice of Proposed Rulemaking received over 43,000 public comments, predominantly supporting rescheduling.

Department of Health and Human Services

The Food and Drug Administration, operating within HHS, conducts the scientific and medical evaluation required for scheduling decisions under 21 U.S.C. § 811(b). FDA Commissioner Robert Califf oversaw the eight-factor analysis examining abuse potential, scientific evidence of pharmacological effect, current scientific knowledge, history and pattern of abuse, scope and significance of abuse, and risk to public health. The FDA's August 2023 recommendation to reschedule acknowledged accepted medical use based on approved drugs containing cannabis-derived compounds, including Epidiolex (cannabidiol) for epilepsy and Marinol (dronabinol) for chemotherapy-induced nausea.

Congressional Leaders

Senate Majority Leader Chuck Schumer has championed comprehensive legalization since 2018, introducing the Cannabis Administration and Opportunity Act with Senators Cory Booker and Ron Wyden. The trio represents the Senate's most vocal reform advocates, though Schumer has faced resistance from moderate Democrats and nearly unified Republican opposition. House members including Representatives Earl Blumenauer, Barbara Lee, and Dave Joyce co-chair the Congressional Cannabis Caucus, founded in 2017. Joyce, a Republican from Ohio, represents bipartisan reform efforts, co-sponsoring the SAFE Banking Act and supporting research access. Representative Nancy Mace introduced the States Reform Act in November 2021, a Republican-authored legalization framework emphasizing states' rights and limited federal taxation. Opposition centers on Senate Republicans including Minority Leader Mitch McConnell, who has blocked floor votes on banking and legalization measures, and Senator John Cornyn, who has cited concerns about impaired driving and youth access.

Industry Organizations

The National Cannabis Industry Association, founded in 2010, represents over 1,800 member businesses and advocates for federal reform through lobbying and coalition-building. The U.S. Cannabis Council, formed in 2020 through a merger of major trade groups, focuses on multi-state operators and national policy. The Cannabis Trade Federation emphasizes banking access and tax reform. State-level operators including Curaleaf, Green Thumb Industries, Trulieve, Cresco Labs, and Verano Holdings collectively operate over 900 dispensaries and command $8.4 billion in annual revenue. These multi-state operators fund lobbying efforts and have contributed over $18 million to federal candidates since 2018, according to OpenSecrets data.

Reform Advocacy Groups

The National Organization for the Reform of Marijuana Laws, founded in 1970, represents the longest-running cannabis advocacy organization, focusing on decriminalization and legalization. The Drug Policy Alliance, founded in 2000, emphasizes criminal justice reform and harm reduction. The Marijuana Policy Project, founded in 1995, has supported state ballot initiatives and federal legislation. Veterans advocacy groups including Iraq and Afghanistan Veterans of America have pressed for VA physician access to recommend cannabis, citing high rates of PTSD and opioid dependence among veterans.

Opposition Groups

Smart Approaches to Marijuana, founded in 2013 by former Representative Patrick Kennedy and psychiatrist Kevin Sabet, opposes legalization while supporting decriminalization. The organization argues that commercial legalization increases youth access, impaired driving, and cannabis use disorder. The Community Anti-Drug Coalitions of America and the National Sheriffs' Association have similarly opposed legalization, citing public health and law enforcement concerns.

Legal and Regulatory Framework

Federal cannabis prohibition rests on the Controlled Substances Act's classification of cannabis as a Schedule I drug under 21 U.S.C. § 812, creating conflicts with state laws, banking regulations, tax codes, and immigration statutes that comprehensive reform must address. The Controlled Substances Act established five schedules based on abuse potential, accepted medical use, and safety. Schedule I substances must have high abuse potential, no currently accepted medical use in treatment in the United States, and lack of accepted safety for use under medical supervision. The Attorney General, through the DEA, may reschedule substances through rulemaking under 21 U.S.C. § 811, considering eight factors including scientific evidence, abuse patterns, and international treaty obligations. The Supremacy Clause of Article VI establishes that federal law preempts conflicting state law. Despite state legalization, federal prohibition remains enforceable. The Rohrabacher-Farr Amendment, first passed in 2014 and renewed annually through appropriations bills, prohibits the Department of Justice from using funds to prevent states from implementing medical cannabis laws. The provision does not protect adult-use programs or create affirmative rights for individuals. Internal Revenue Code Section 280E, enacted in 1982 following a Tax Court case involving a cocaine trafficker, prohibits businesses from deducting ordinary expenses if they traffic in Schedule I or II substances. Cannabis businesses may deduct cost of goods sold but not rent, salaries, marketing, or other operating expenses. The provision creates effective tax rates of 70% or higher, according to industry analyses. The Bank Secrecy Act requires financial institutions to file Suspicious Activity Reports for transactions involving illegal activity. The Financial Crimes Enforcement Network issued guidance in 2014 establishing "marijuana-limited" and "marijuana-priority" SAR categories, allowing banks to serve cannabis businesses while maintaining compliance. Despite the guidance, most institutions avoid the sector due to federal illegality and regulatory uncertainty. The Immigration and Nationality Act at 8 U.S.C. § 1182(a)(2)(A)(i)(II) renders individuals inadmissible if they have violated any law relating to a controlled substance. U.S. Citizenship and Immigration Services has denied naturalization applications and green card renewals for individuals working in state-legal cannabis industries. Canadian citizens have been barred from entering the United States after admitting cannabis use or investment in Canadian cannabis companies. Federal firearms law at 18 U.S.C. § 922(g)(3) prohibits unlawful users of controlled substances from possessing firearms. The Bureau of Alcohol, Tobacco, Firearms and Explosives issued guidance in 2011 stating that medical cannabis cardholders are prohibited persons. The Ninth Circuit upheld the prohibition in Wilson v. Lynch (2016).

State-by-State Status and Federal Implications

As of May 2026, 38 states have authorized medical cannabis programs and 24 states permit adult-use sales, creating a patchwork of regulations that federal reform would harmonize or complicate depending on the approach.

Adult-Use States

California launched adult-use sales on January 1, 2018, following Proposition 64's approval in November 2016. Adults 21 and older may possess up to one ounce of flower and eight grams of concentrate. The state imposes a 15% excise tax and cultivation taxes of $10.08 per ounce for flower and $3.00 per ounce for leaves. California generated $1.1 billion in cannabis tax revenue in 2025, though illegal market competition remains significant, with estimates suggesting illicit sales comprise 50-60% of total consumption. Colorado pioneered regulated adult-use sales beginning January 1, 2014. Possession limits match California at one ounce. The state imposes a 15% retail excise tax and 15% retail sales tax. Colorado collected $423 million in cannabis tax revenue in 2025, funding school construction, drug treatment, and law enforcement. The market has matured with over 1,400 licensed retailers and wholesale prices declining from $2,000 per pound in 2014 to $800 per pound in 2025. Illinois launched sales on January 1, 2020, following the Cannabis Regulation and Tax Act signed by Governor J.B. Pritzker. The state implements social equity provisions requiring 20% of licenses for applicants from communities with high arrest rates and offering technical assistance and low-interest loans. Illinois collected $445 million in cannabis tax revenue in 2025, with 25% allocated to the Restore, Reinvest, and Renew Program supporting community development. New York began adult-use sales on December 29, 2022, after years of regulatory delays. The state prioritizes social equity applicants, particularly individuals with prior cannabis convictions. New York imposes a THC-based tax: 0.5 cents per milligram for flower, 0.8 cents per milligram for concentrates, 3 cents per milligram for edibles. The state collected $187 million in cannabis tax revenue in 2025, below projections due to slow licensing and continued illegal market activity. Ohio voters approved Issue 2 on November 7, 2023, with 57% support, authorizing adult-use possession and sales. The Division of Cannabis Control began accepting applications in 2024, with sales launching in early 2025. Adults may possess up to 2.5 ounces. Ohio imposes a 10% excise tax, generating an estimated $276 million in the first year. Additional adult-use states include Alaska, Arizona, Connecticut, Delaware, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nevada, New Jersey, New Mexico, Oregon, Rhode Island, Vermont, Virginia, and Washington, plus the District of Columbia and Guam.

Medical-Only States

Florida operates the nation's largest medical-only program with over 890,000 registered patients as of May 2026. Amendment 2, approved in 2016, authorized medical use for qualifying conditions including cancer, epilepsy, glaucoma, HIV/AIDS, PTSD, ALS, Crohn's disease, Parkinson's disease, and multiple sclerosis. Patients may possess up to a 70-day supply as determined by physicians. A adult-use ballot measure is expected in November 2026. Texas maintains a restrictive Compassionate Use Program limited to patients with intractable epilepsy, terminal cancer, PTSD, and autism, with THC content capped at 1%. The program served 66,000 patients as of 2025. Broader reform faces opposition from Republican legislative leadership despite growing public support. Additional medical-only states include Alabama, Arkansas, Georgia, Hawaii, Louisiana, Mississippi, Missouri, Montana, New Hampshire, New Mexico, North Dakota, Oklahoma, Pennsylvania, South Dakota, Utah, and West Virginia.

Non-Legal States

Six states maintain complete prohibition: Idaho, Kansas, Nebraska, South Carolina, Wisconsin, and Wyoming. These states create complications for interstate travel and commerce, as patients and products crossing state lines violate federal law even when traveling between legal states.

Market and Business Implications of Federal Reform

Federal legalization would unlock interstate commerce, institutional investment, and banking access while eliminating Section 280E tax burdens—transforming a $30 billion fragmented state market into a unified national industry potentially exceeding $75 billion by 2030. Section 280E elimination represents the most immediate financial impact. Multi-state operators currently pay effective tax rates of 70-85% on earnings before interest, taxes, depreciation, and amortization. Curaleaf reported $153 million in federal income tax expense on $1.3 billion in revenue in 2024, an effective rate of 11.8% on revenue but over 70% on operating income. Rescheduling to Schedule III would eliminate 280E, allowing normal business deductions and reducing effective rates to 21-25%, freeing hundreds of millions in capital for expansion and price competition. Banking access would reduce operational costs and security risks. Cash-intensive operations require armored transport, vault storage, and security personnel, adding 5-8% to operating costs according to industry estimates. Electronic payments reduce transaction costs, enable customer credit, and facilitate payroll. The SAFE Banking Act would provide explicit safe harbor for institutions serving state-legal businesses, potentially bringing thousands of banks and credit unions into the sector. Interstate commerce represents the largest structural shift. Current prohibition forces each state to maintain closed-loop cultivation, processing, and retail systems. Federal legalization would allow cannabis to move across state lines like alcohol, enabling cultivation to concentrate in optimal climates—California, Oregon, and Colorado—while processing and retail expand nationwide. Wholesale prices would decline as supply chains rationalize, benefiting consumers but pressuring operators in high-cost states. Capital markets would open to institutional investment. Cannabis companies cannot list on the New York Stock Exchange or Nasdaq due to federal illegality, forcing them to trade on Canadian exchanges or over-the-counter markets with limited liquidity. Federal legalization would enable major exchange listings, index inclusion, and institutional ownership. Pension funds, mutual funds, and insurance companies currently prohibited from cannabis exposure could allocate capital, potentially driving $50-100 billion in market capitalization growth. Consolidation would accelerate as larger operators acquire regional competitors and private equity enters the sector. The fragmented market—with over 15,000 licensed businesses across cultivation, processing, and retail—would consolidate toward the alcohol industry's structure, where the top 10 companies control 60% of market share. Multi-state operators including Curaleaf, Green Thumb Industries, Trulieve, Cresco Labs, and Verano would likely emerge as dominant national players, while craft cultivators and boutique retailers serve premium segments. Pharmaceutical integration represents a longer-term implication. Schedule III classification would enable FDA-approved cannabis-derived drugs to enter traditional pharmacy channels, competing with dispensaries. GW Pharmaceuticals' Epidiolex, approved in 2018 for epilepsy, generated $838 million in 2024 sales. Additional FDA approvals for PTSD, chronic pain, and chemotherapy side effects could shift medical cannabis from dispensaries to CVS and Walgreens, bifurcating medical and adult-use markets. Employment would expand from 428,000 direct jobs in 2025 to potentially 1.1 million by 2030 under federal legalization, according to Leafly's annual jobs report. Cultivation, processing, retail, testing, security, legal, and compliance roles would grow, while ancillary sectors including real estate, construction, equipment manufacturing, and software would benefit from industry expansion.

What Experts Say About Federal Reform

Policy experts, industry leaders, and researchers emphasize that federal reform's structure—whether rescheduling, descheduling, or comprehensive legislation—will determine outcomes for public health, criminal justice, and market development. According to the Drug Policy Alliance, rescheduling to Schedule III represents incremental progress but fails to address core issues. The organization's director of national affairs, Queen Adesuyi, has stated that Schedule III maintains federal prohibition, continues criminal penalties for unauthorized possession and distribution, and preserves state-federal conflicts. The organization advocates for descheduling through congressional legislation that includes expungement, social equity provisions, and public health frameworks. The National Cannabis Industry Association supports comprehensive legislation over administrative rescheduling. The organization's position emphasizes that rescheduling alone does not authorize state programs, enable interstate commerce, or resolve banking access. Congressional legislation could establish a federal regulatory framework similar to alcohol under the Federal Alcohol Administration Act, with the Alcohol and Tobacco Tax and Trade Bureau overseeing production and the FDA regulating health claims. Research institutions emphasize that Schedule III would expand research access by removing DEA cultivation monopolies and NIDA review requirements. The Multidisciplinary Association for Psychedelic Studies has documented that current Schedule I restrictions delay studies by 18-24 months and limit available cannabis to NIDA's single contracted cultivator at the University of Mississippi, which produces material that researchers describe as lower quality than state-market products. Schedule III would allow universities and private companies to cultivate research-grade cannabis under DEA registration, similar to other Schedule III substances like ketamine and testosterone. Criminal justice reform advocates stress that rescheduling does not expunge past convictions or prevent future arrests. The Last Prisoner Project, which advocates for cannabis prisoner release and record expungement, notes that over 40,000 individuals remain incarcerated for federal cannabis offenses, with hundreds of thousands more carrying state convictions. Comprehensive legislation could include automatic expungement for possession offenses and resentencing provisions for cultivation and distribution cases. Public health researchers express concerns about commercialization without adequate regulation. The American Academy of Pediatrics has stated that legalization should include restrictions on marketing to youth, potency limits for certain products, and funding for prevention and treatment programs. Research from states with legal markets shows increases in adult use but mixed evidence on youth use, with some studies showing declines and others showing increases depending on regulatory stringency. Financial analysts project that federal legalization would drive significant market consolidation and valuation increases. Cowen & Company estimates that the total addressable market would grow from $30 billion in state-legal sales to $75-100 billion including currently illegal states and increased consumption from reduced prices. The firm projects that multi-state operators would see EBITDA margins expand from 25-30% currently to 35-40% post-280E elimination, driving equity valuations up 200-300%.

What's Next: Timeline and Decision Points

Federal cannabis reform faces critical decision points in 2026-2027, including DEA rescheduling finalization, congressional elections, and potential comprehensive legislation, with outcomes ranging from incremental Schedule III rescheduling to full descheduling and regulatory framework establishment. The DEA rescheduling process represents the most immediate catalyst. Following the May 2024 Notice of Proposed Rulemaking and public comment period, the agency must issue a final rule. Administrative law typically requires 6-12 months from comment period closure to final rule publication. Industry observers expect a final rule by late 2026, though legal challenges from prohibition advocates or reform advocates dissatisfied with Schedule III could delay implementation into 2027. If rescheduling proceeds to Schedule III, the immediate effects would include Section 280E elimination, expanded research access, and continued state-federal conflicts. The change would not authorize state programs under federal law, enable interstate commerce, or resolve banking access. The FDA would gain authority to regulate cannabis-derived drugs through the standard approval process, potentially leading to prescription cannabis products competing with dispensaries. Congressional action depends on the November 2026 elections. If Democrats maintain Senate control and gain House seats, comprehensive legalization legislation could advance in 2027. The Cannabis Administration and Opportunity Act or a revised version could receive floor votes, though passage would require 60 Senate votes to overcome filibuster unless Democrats eliminate the filibuster for cannabis legislation. If Republicans gain control of one or both chambers, incremental measures like the SAFE Banking Act become more likely than comprehensive legalization. State ballot measures in 2026 include adult-use initiatives in Florida, where polling shows 64% support, and potentially Arkansas, Idaho, and Nebraska. Florida's Amendment 3, requiring 60% approval, would create the nation's largest adult-use market with 22 million residents. Approval would increase pressure on federal reform by demonstrating continued public support in a politically competitive state. International developments may influence U.S. policy. The United Nations Commission on Narcotic Drugs reclassified cannabis in December 2020, removing it from Schedule IV of the 1961 Single Convention on Narcotic Drugs while maintaining Schedule I status. Germany launched adult-use legalization in April 2024, joining Canada, Uruguay, Mexico, and Malta. Continued international normalization could reduce U.S. policymakers' concerns about treaty obligations and diplomatic complications. Legal challenges to prohibition may emerge through novel theories. Some advocates argue that the Controlled Substances Act's Schedule I criteria are unconstitutional as applied to cannabis given widespread medical use and state legalization. Others suggest that the Tenth Amendment's anti-commandeering doctrine prevents federal enforcement of prohibition in states that have legalized. While these theories face significant legal hurdles, a successful challenge could force congressional action. The 2028 presidential election represents another inflection point. Democratic candidates will likely support legalization, while Republican positions remain divided between libertarian-leaning candidates supporting states' rights and social conservatives opposing reform. A reform-supportive president could direct the DEA to deschedule cannabis entirely or decline to enforce prohibition in legal states, though such actions would face legal challenges.

Further Reading and Primary Sources

• Controlled Substances Act, 21 U.S.C. § 801 et seq. — https://www.govinfo.gov/content/pkg/USCODE-2021-title21/pdf/USCODE-2021-title21-chap13.pdf
• DEA Notice of Proposed Rulemaking on Cannabis Rescheduling (May 2024) — https://www.federalregister.gov/
• HHS Recommendation to Reschedule Cannabis (August 2023) — https://www.hhs.gov/
• Congressional Research Service, "Marijuana: Medical and Retail—Selected Legal Issues" — https://crsreports.congress.gov/
• Cannabis Administration and Opportunity Act, S. 4591 (117th Congress) — https://www.congress.gov/bill/117th-congress/senate-bill/4591
• SAFE Banking Act, H.R. 1996 (118th Congress) — https://www.congress.gov/bill/118th-congress/house-bill/1996
• Internal Revenue Code Section 280E — https://www.law.cornell.edu/uscode/text/26/280E
• FinCEN Guidance on Marijuana-Related Businesses (February 2014) — https://www.fincen.gov/resources/statutes-regulations/guidance/bsa-expectations-regarding-marijuana-related-businesses
• National Conference of State Legislatures, "State Medical Cannabis Laws" — https://www.ncsl.org/health/state-medical-cannabis-laws
• Congressional Budget Office, "Budgetary Effects of Legalizing Marijuana" — https://www.cbo.gov/
• Drug Policy Alliance, "Federal Marijuana Policy Reform" — https://drugpolicy.org/issues/marijuana-legalization-and-regulation
• National Cannabis Industry Association Policy Positions — https://thecannabisindustry.org/
• American Civil Liberties Union, "Marijuana Arrests by the Numbers" — https://www.aclu.org/issues/smart-justice/sentencing-reform/marijuana-arrests-numbers
• Marijuana Policy Project, "Federal Marijuana Policy" — https://www.mpp.org/issues/legislation/federal-marijuana-policy/